Acting US FDA Chief Sharpless Pledges "Full Speed Ahead" On Agency's Current Agenda
In his first speech to agency staff, Acting Commissioner Norman Sharpless says FDA will continue working on issues including drug pricing and opioids – and he is not approaching the post like a temporary caretaker.
You may also be interested in...
US FDA commissioner nominee could face a slew of questions about non-drug issues such as e-cigarette regulation, which may mean pharma must read between the lines for insight into his drug-related policy stances.
Acting Commissioner Giroir Emphasizes 'Transitional' Period, Suggesting Time At US FDA Will Be Short
Giroir's memo to FDA staff also says intends to coordinate with prior acting commissioner Norman Sharpless to ensure current activities continue.
Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.